There are currently 27 active clinical trials seeking participants for Neuroendocrine Tumors research studies. The states with the highest number of trials for Neuroendocrine Tumors participants are California, New York, Texas and Florida.
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
NCT05636618
Recruiting
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2024
Locations: Mayo Clinic, Jacksonville, Florida +7 locations
Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Tumor Carcinoid, Carcinoid Tumor of GI System, Carcinoid Tumor, Paraganglioma, Pheochromocytoma
Register for Updates
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
NCT05997056
Recruiting
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +3 locations
Conditions: Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
Register for Updates
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
NCT04090034
Recruiting
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Clinical Research Institute at Methodist Health System, Dallas, Texas +1 locations
Conditions: Neuroendocrine Tumors
Register for Updates
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT05000294
Recruiting
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is not currently thought to be an effective intervention in the treatment of several immunologically "cold" tumors such as prostate cancer, biliary tract cancers, soft tissue sarcomas, well-differentiated... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/13/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Register for Updates
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
NCT06204159
Recruiting
The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE. • Is there a difference in CT appearance with delivery in the type of catheter used during the TACE procedure? Participants will be asked to undergo a TACE procedure, a CT scan and review of their medical record to compare End Hole and TriNav cathete... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Hepatocellular Carcinoma, Neuroendocrine Tumors
Register for Updates
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
NCT05475210
Recruiting
This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroendocrine Tumors
Register for Updates
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774
Recruiting
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Massive Bio, Inc, New York, New York
Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
All
Ages:
Between 19 years and 110 years
Trial Updated:
02/29/2024
Locations: Penrose Cancer Center, Colorado Springs, Colorado +83 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
F-Tryptophan PET/CT in Human Cancers
NCT05556473
Recruiting
Imaging procedures such as 1-(2-[18F]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer
Register for Updates
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT04848337
Recruiting
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: City of Hope, Duarte, California +4 locations
Conditions: Prostate Cancer Metastatic, Neuroendocrine Tumors
Register for Updates
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
NCT05746208
Recruiting
This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 2019. Recent data suggest an equivalent subtype exists in the lungs (NEC with carcinoid morphology). WD G3 NETs can occur de novo as well as the result of grade progression over time. This is a single arm, multi-site, Phase... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Register for Updates
CapTemY90 for Grade 2 NET Liver Metastases
NCT04339036
Recruiting
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: CARTI Cancer Center, Little Rock, Arkansas +2 locations
Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Register for Updates